EverSource Wealth Advisors’s ADC Therapeutics ADCT Stock Holding History

EverSource Wealth Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$691	Sell	646 -320	-33%	-$933	﹤0.01%	4068
2026 Q1	$3.62K	Buy	966 +8	+0.8%	+$32	﹤0.01%	3412
2025 Q4	$3.38K	Buy	958 +11	+1%	+$45	﹤0.01%	3288
2025 Q3	$3.79K	Buy	947 +83	+10%	+$262	﹤0.01%	3273
2025 Q2	$2.31K	Buy	864 +633	+274%	+$1.33K	﹤0.01%	3457
2025 Q1	$325	Buy	231 +154	+200%	+$262	﹤0.01%	3584
2024 Q4	$153	Buy	+77	New	+$201	﹤0.01%	3482

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EverSource Wealth Advisors's ADCT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its ADC Therapeutics (ADCT) stake by 33% in Q2 2026, selling an estimated $933 and leaving 646 shares worth $691. The position accounts for ﹤0.01% of the portfolio, ranked #4068.

EverSource Wealth Advisors first reported a position in ADCT in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.79K in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

EverSource Wealth Advisors held 646 shares of ADC Therapeutics worth $691 as of Q2 2026.
EverSource Wealth Advisors sold 320 ADC Therapeutics shares in Q2 2026, an estimated $933.
ADC Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4068 holding.
EverSource Wealth Advisors first reported a position in ADC Therapeutics in Q4 2024 and has held it in 7 quarters since.
EverSource Wealth Advisors's ADC Therapeutics position peaked at $3.79K in Q3 2025.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.